Core Viewpoint - Huanren Pharmaceutical's wholly-owned subsidiary, Anhui Hengxing Pharmaceutical, has received approval from the National Medical Products Administration for the production and sale of "Isoproterenol Hydrochloride" in the domestic market [1] Group 1 - The approval includes the issuance of a "Chemical Raw Material Drug Listing Application Approval Notice" [1] - The raw material drug has met the relevant technical standards for raw material drug review in the country [1] - This development allows the company to expand its product offerings in the domestic market [1]

Core Viewpoint - Hainan Pharmaceutical's subsidiary, Anhui Hengxing Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of "Isoproterenol Hydrochloride" [1] Company Summary - The approval of Isoproterenol Hydrochloride, a non-selective β-adrenergic agonist, will enhance the company's active pharmaceutical ingredient (API) product line [1] - This product is primarily used for treating cardiogenic or infectious shock, complete atrioventricular block, cardiac arrest, and acute bronchial asthma attacks [1] - The addition of this product is expected to improve the company's market competitiveness [1]

Core Viewpoint - Huanren Pharmaceutical's subsidiary, Anhui Hengxing Pharmaceutical, has received approval from the National Medical Products Administration for the marketing application of "Isoproterenol Hydrochloride" [1] Group 1: Company Developments - The approval pertains to Isoproterenol Hydrochloride, a non-selective β-adrenergic agonist that strongly stimulates both β1 and β2 receptors [1] - Isoproterenol Hydrochloride is clinically used for treating conditions such as cardiogenic or infectious shock, complete atrioventricular block, cardiac arrest, and acute bronchial asthma attacks [1]

Core Viewpoint - Huaren Pharmaceutical's subsidiary, Anhui Hengxing Pharmaceutical, has received approval from the National Medical Products Administration for the marketing application of Isoproterenol Hydrochloride, a non-selective β-adrenergic agonist used in various clinical treatments [1] Group 1 - The approved drug, Isoproterenol Hydrochloride, is known for its strong positive inotropic and chronotropic effects, as well as its bronchodilator properties [1] - Clinical applications of Isoproterenol Hydrochloride include treatment for cardiogenic or septic shock, complete atrioventricular block, cardiac arrest, and acute bronchial asthma attacks [1]

Core Viewpoint - Huaren Pharmaceutical's subsidiary, Anhui Hengxing Pharmaceutical, has received approval from the National Medical Products Administration for the marketing application of Isoproterenol Hydrochloride, indicating a significant advancement in the company's product portfolio and potential market opportunities [1]. Group 1 - The approved drug, Isoproterenol Hydrochloride, is a non-selective β-adrenergic agonist that strongly stimulates both β1 and β2 receptors, showcasing powerful positive inotropic, positive chronotropic, and bronchodilator effects [1]. - The clinical applications of Isoproterenol Hydrochloride primarily include treatment for cardiogenic or septic shock, complete atrioventricular block, cardiac arrest, and acute bronchial asthma attacks [1].

证券代码：300110 证券简称：华仁药业 公告编号：2025-059 华仁药业股份有限公司 关于全资子公司盐酸异丙肾上腺素原料药获得上市申请 批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华仁药业股份有限公司（以下简称"公司"）全资子公司安徽恒星制药 有限公司（以下简称"安徽恒星制药"）收到国家药品监督管理局核准签发的"盐 酸异丙肾上腺素"《化学原料药上市申请批准通知书》（通知书编号： 2025YS00767）。现将相关情况公告如下： 一、原料药登记信息 1．通用名称：盐酸异丙肾上腺素 2．英文名/拉丁名：Isoprenaline Hydrochloride 3．化学原料药注册标准编号：YBY68912025 4．包装规格：1kg/桶 5．申请事项：境内生产化学原料药上市申请 6．审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执 行。 7．生产企业 名称：安徽恒星制药有限公司 地址：合肥市包河工业区纬五路 15 号 二、药品的其他情况 盐酸异丙肾上 ...

Group 1 - The company announced that its first extraordinary general meeting of shareholders for 2025 will be held on September 1, 2025 [2] - The meeting will review multiple proposals, including the election of an independent director for the eighth board of directors [2]

Core Viewpoint - Huaren Pharmaceutical announced the approval of its subsidiary Anhui Hengxing Pharmaceutical's application for the chemical raw material "Nafamostat Mesilate" by the National Medical Products Administration [2] Group 1 - The approval notification for "Nafamostat Mesilate" marks a significant milestone for Huaren Pharmaceutical and its subsidiary [2] - This approval allows the company to expand its product offerings in the pharmaceutical market [2] - The development reflects the company's ongoing commitment to innovation and compliance with regulatory standards [2]

Core Viewpoint - Huaren Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for its subsidiary Anhui Hengxing Pharmaceutical to market "Nefopam Hydrochloride," a non-narcotic, non-addictive analgesic drug [1] Group 1: Product Approval - Anhui Hengxing Pharmaceutical has been granted the "Chemical Raw Material Drug Marketing Application Approval Notice" for Nefopam Hydrochloride, with notification number 2025YS00762 [1] Group 2: Product Characteristics - Nefopam Hydrochloride is a powerful analgesic with mild antipyretic and muscle relaxant effects, primarily used for treating acute pain, especially postoperative pain [1] - The drug can also serve as an adjunct in local anesthesia and needle anesthesia [1] - It is not classified as a psychoactive analgesic, thus eliminating concerns regarding addiction [1] Group 3: Clinical Usage - Nefopam Hydrochloride has been widely used in clinical settings for severe pain due to its effective pain relief, minimal side effects, and characteristics of rapid onset and prolonged action [1]

北京植德（青岛）律师事务所 关于华仁药业股份有限公司 2025 年第一次临时股东会的 法律意见书 植德青（会）字[2025]0002 号 二〇二五年九月 山东省青岛市崂山区香岭路 1 号资源博雅广场 4 号楼 10 层 邮编：266000 10th Floor, Building 4, Resources Boya Plaza, No.1 Xiangling Road, Laoshan District, Qingdao City, Shandong Province 266000 P.R.C www.meritsandtree.com 北京植德（青岛）律师事务所 关于华仁药业股份有限公司 2025 年第一次临时股东会的 法律意见书 植德青（会）字[2025]0002 号 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《律师事务所从事 证券法律业务管理办法》（以下简称"《证券法律业务管理办法》"）、《律师 事务所证券法律业务执业规则（试行）》（以下简称"《证券 ...